When modeled, the predicted reduction in PVR from baseline with sotatercept, an activin ligand trap (28), in a PAH population is around 210 dynes · s/cm5 (approximately 2.6 Wood units) (33). The gene discussed is INHBE; the disease is pulmonary arterial hypertension.